Valuation: Senzime AB

Market Cap 582M 60.8M 52.84M 49.33M 45.29M 85.39M 5.8B 86.88M 228M 2.89B 228M 223M 9.53B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 582M 60.8M 52.84M 49.33M 45.29M 85.39M 5.8B 86.88M 228M 2.89B 228M 223M 9.53B EV / Sales 2026 *
4.56x
EV / Sales 2027 * 2.85x
Free-Float
40.74%
Yield 2026 *
-
Yield 2027 * -
1 day-1.35%
1 week+1.39%
Current month-1.35%
1 month-13.92%
3 months-22.91%
6 months-25.66%
Current year-32.41%
1 week 3.6
Extreme 3.6
3.82
1 month 3.54
Extreme 3.545
4.4
Current year 3.54
Extreme 3.545
6
1 year 3.54
Extreme 3.545
7.22
3 years 3.54
Extreme 3.545
9.6
5 years 2.6
Extreme 2.605
24.8
10 years 2.6
Extreme 2.605
28.5
Manager TitleAgeSince
Chief Executive Officer 53 03/05/2023
Director of Finance/CFO 56 01/01/2022
Chief Tech/Sci/R&D Officer 50 01/01/2023
Director TitleAgeSince
Chairman 53 03/05/2023
Director/Board Member 70 01/01/2016
Director/Board Member 63 05/03/2020
Date Insider Type Main position Quantity % Market Cap.
9/12/25 Buy

Director

15,000 0.0095%
9/12/25 Sell

Director

15,000 0.0095%
28/11/25 Buy

Director

15,900 0.0101%
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+1.39%-48.01%-28.43% 60.99M
+1.34%+2.52%-17.56%-0.39% 183B
+1.51%+2.92%-3.30%+2.59% 109B
-0.95%-0.89%+5.02%+61.15% 60.57B
+2.37%+2.85%+44.34%+56.22% 51.8B
+2.77%+7.10%-4.86%-36.65% 45.64B
+3.03%+1.94% - - 33.22B
+4.63%+19.00%+14.50%-28.48% 31.49B
+2.05%+5.04%+45.95%-5.89% 24B
+1.86%+6.52%+1.84%+3.17% 22.26B
Average +1.75%+4.34%+4.22%+2.59% 56.12B
Weighted average by Cap. +1.79%+3.37%+0.77%+7.93%

Financials

2026 *2027 *
Net sales 128M 13.35M 11.6M 10.83M 9.94M 18.75M 1.27B 19.07M 50.01M 634M 50.14M 49.02M 2.09B 204M 21.32M 18.53M 17.3M 15.88M 29.95M 2.03B 30.47M 79.9M 1.01B 80.09M 78.32M 3.34B
Net income -68.9M -7.2M -6.26M -5.84M -5.36M -10.11M -686M -10.29M -26.98M -342M -27.05M -26.45M -1.13B -36.8M -3.85M -3.34M -3.12M -2.87M -5.4M -367M -5.5M -14.41M -183M -14.45M -14.13M -603M
Net Debt - -
Logo Senzime AB
Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Employees
59
Date Price Change Volume
04/08/26 SEK 3.650 -1.35% 101,833
31/07/26 SEK 3.700 0.00% 119,337
30/07/26 SEK 3.700 +1.23% 39,070
29/07/26 SEK 3.655 0.00% 88,545
28/07/26 SEK 3.655 -0.68% 58,445

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SEZI Stock